Clinical trial
Raloxifene Use for The Heart
NCT00190593 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190593 |
|---|---|
| Title | Raloxifene Use for The Heart |
| Official title | Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cardiovascular Diseases, Breast Neoplasms |
| Intervention type | Drug |
| Interventions | raloxifene, placebo |
| Enrollment | 10,000 |
| Start date | Jun 1, 1998 |
| Completion | Nov 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: